A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without LY2835219, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without LY2835219, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Abemaciclib (Primary) ; Fulvestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms MONARCH 2
  • Sponsors Eli Lilly
  • Most Recent Events

    • 09 Dec 2017 Results of exploratory subgroup analysis of MONARCH 1, 2, 3 studies assessing efficacy and safety of abemaciclib in breast cancer patients with liver metastases presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 09 Dec 2017 Results of an exploratory analysis of combined data from the MONARCH 2 and 3 studies presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 28 Sep 2017 Based on the data from this trial, the US FDA has approved Verzenio (abemaciclib) in combination with fulvestrant to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient's hormones (endocrine therapy), as reported in a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top